Literature DB >> 18355768

Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats.

David J Leehey1, Ashok K Singh, Joseph P Bast, Periannan Sethupathi, Rekha Singh.   

Abstract

Substantial evidence suggests that the intrarenal renin-angiotensin system (RAS) plays a role in the pathogenesis of diabetic nephropathy. Although the glomerular RAS is activated in the streptozotocin (STZ)-diabetic rat, the status of the glomerular RAS in the Zucker diabetic fatty (ZDF) rat, which is a commonly used genetic model of diabetes, is not known. Angiotensinogen (AGT), angiotensin II (Ang II), angiotensin converting enzyme (ACE), and angiotensin converting enzyme 2 (ACE2) were measured in glomeruli isolated from 4-week-old STZ-diabetic rats and 32-week-old ZDF rats. Glomerular injury was evaluated by histopathologic methods. Both STZ-diabetic and ZDF rats exhibited marked hyperglycemia and renal hypertrophy, but only ZDF rats demonstrated proteinuria and glomerulosclerosis. Glomerular AGT and Ang II levels were increased significantly in STZ-diabetic compared with nondiabetic control rats, accompanied by a reduction in ACE2 activity. In contrast, glomerular AGT, Ang II, and ACE2 were similar in ZDF rats and lean controls. ACE levels were not affected by diabetes in either diabetic model. In conclusion, the glomerular RAS is activated in the STZ diabetic rat but not in the ZDF rat despite a similar degree of hyperglycemia. The mechanism of nephropathy in the ZDF rat may involve factors other than hyperglycemia and RAS activation, such as hypertension and hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355768     DOI: 10.1016/j.trsl.2008.01.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  27 in total

1.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

Authors:  Esam S B Salem; Nadja Grobe; Khalid M Elased
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-22

Review 2.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

3.  Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes.

Authors:  Liliya M Yamaleyeva; Shea Gilliam-Davis; Igor Almeida; K Bridget Brosnihan; Sarah H Lindsey; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-29

4.  Angiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease.

Authors:  Maki Urushihara; Hiroyuki Kobori
Journal:  Int J Clin Med       Date:  2011-09-01

5.  Functional and molecular evidence for expression of the renin angiotensin system and ADAM17-mediated ACE2 shedding in COS7 cells.

Authors:  Nadja Grobe; Mauricio Di Fulvio; Nada Kashkari; Harshita Chodavarapu; Hari K Somineni; Richa Singh; Khalid M Elased
Journal:  Am J Physiol Cell Physiol       Date:  2015-03-04       Impact factor: 4.249

6.  High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB.

Authors:  Nishant P Visavadiya; Yanzhang Li; Shuxia Wang
Journal:  Nephron Exp Nephrol       Date:  2010-09-01

Review 7.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

Review 8.  ACE2 alterations in kidney disease.

Authors:  María José Soler; Jan Wysocki; Daniel Batlle
Journal:  Nephrol Dial Transplant       Date:  2013-08-16       Impact factor: 5.992

9.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

Review 10.  Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.

Authors:  Hiroyuki Kobori; Maki Urushihara
Journal:  Pflugers Arch       Date:  2012-08-24       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.